BliNK Biomedical

Belkins
BliNK Biomedical is a biotech company developing naturally occurring therapeutic antibodies for the treatment of life threatening diseases such as cancer.

Related News

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

Labiotech | January 15, 2020

news image

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More

CDI LABS ANNOUNCES THE ADDITION OF ITS SARS-COV-2 (COVID19) ASSAY PLATFORM

PR Newswire | August 21, 2020

news image

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...

Read More

CAMENA BIOSCIENCE HITS DNA SYNTHESIS MILESTONE

Labiotech | February 06, 2020

news image

Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....

Read More

CELL AND GENE THERAPY

VIPERGEN PUBLISHES POWERFUL NEW DRUG DISCOVERY APPROACH FOR THE FIRST TIME, SCREENING DNA-ENCODED SMALL-MOLECULE LIBRARIES (DELS) INSIDE LIVING CELLS

Vipergen | February 18, 2021

news image

Vipergen ApS announced today a published study depicting a ground-breaking new medication revelation approach that empowers, interestingly, screening DNA-encoded small-molecule libraries (DELs) inside living cells. The study, published in the peer-reviewed Journal of the American Chemical Society, highlights the potential of Vipergen's Cellular Binder Trap Enrichment® (cBTE) technology to significantly grow the ability to discover novel small molecules, including against difficult-to-dru...

Read More

Labiotech | January 15, 2020

news image

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More

PR Newswire | August 21, 2020

news image

CDI LABS ANNOUNCES THE ADDITION OF ITS SARS-COV-2 (COVID19) ASSAY PLATFORM

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...

Read More

Labiotech | February 06, 2020

news image

CAMENA BIOSCIENCE HITS DNA SYNTHESIS MILESTONE

Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....

Read More

CELL AND GENE THERAPY

Vipergen | February 18, 2021

news image

VIPERGEN PUBLISHES POWERFUL NEW DRUG DISCOVERY APPROACH FOR THE FIRST TIME, SCREENING DNA-ENCODED SMALL-MOLECULE LIBRARIES (DELS) INSIDE LIVING CELLS

Vipergen ApS announced today a published study depicting a ground-breaking new medication revelation approach that empowers, interestingly, screening DNA-encoded small-molecule libraries (DELs) inside living cells. The study, published in the peer-reviewed Journal of the American Chemical Society, highlights the potential of Vipergen's Cellular Binder Trap Enrichment® (cBTE) technology to significantly grow the ability to discover novel small molecules, including against difficult-to-dru...

Read More